Insilico Medicine, led by scientist Alex Zhavoronkov,

 

Insilico Medicine, led by scientist Alex Zhavoronkov, has administered a groundbreaking therapy for chronic lung disease idiopathic pulmonary fibrosis (IPF) in a Chinese patient.  The drug, INS018_055, is the first-ever "AI-discovered and AI-designed" medication to enter phase 2 clinical trials. Insilico's AI platforms have the potential to double the productivity of major pharmaceutical companies, significantly reducing drug discovery time and costs, according to Zhavoronkov. Insilico has attracted partnerships with major pharmaceutical firms like Sanofi, Fosun, and Johnson & Johnson, which have access to its AI technology. By utilizing generative AI, Insilico swiftly identifies drug targets and designs molecules tailored to combat specific diseases. The global AI in drug discovery market is projected to grow from $1.4B in 2022 to $9.7B by 2032.